STOCK TITAN

Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Jazz Pharmaceuticals plc will participate in upcoming investor conferences including Jefferies London Healthcare Conference, 6th Annual Evercore ISI HealthCONx Conference, and 2023 BofA Leveraged Finance Conference. Audio webcasts of the presentations will be available on the company's website.
Positive
  • None.
Negative
  • None.

DUBLIN, Nov. 1, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following upcoming investor conferences:

Jefferies London Healthcare Conference on Tuesday, November 14, 2023

  • Fireside chat at 4:30 a.m. PT / 7:30 a.m. ET / 12:30 p.m. GMT

6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023

  • Fireside chat at 7:25 a.m. PT / 10:25 a.m. ET / 3:25 p.m. GMT

2023 BofA Leveraged Finance Conference on Wednesday, November 29, 2023

  • Fireside chat at 7:10 a.m. PT / 10:10 a.m. ET / 3:10 p.m. GMT

Audio webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-upcoming-november-investor-conferences-301974348.html

SOURCE Jazz Pharmaceuticals plc

FAQ

What conferences will Jazz Pharmaceuticals participate in?

Jazz Pharmaceuticals will participate in Jefferies London Healthcare Conference, 6th Annual Evercore ISI HealthCONx Conference, and 2023 BofA Leveraged Finance Conference.

Where can I find the webcasts of the presentations?

The audio webcasts of the presentations will be available on the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.

How long will the webcasts be available?

The webcasts will be archived on the website for 30 days.

Jazz Pharmaceuticals, Inc.

NASDAQ:JAZZ

JAZZ Rankings

JAZZ Latest News

JAZZ Stock Data

6.89B
60.45M
2.82%
95.89%
5.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DUBLIN

About JAZZ

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni